共 222 条
[1]
Arangalage D(2017)Survival after fulminant myocarditis induced by immune-checkpoint inhibitors Ann Intern Med 167 683-684
[2]
Delyon J(2018)Combined checkpoint inhibitor-associated myocarditis and pulmonary vasculitis mimicking acute pulmonary embolism Eur Heart J Cardiovasc Imaging 27 155-158
[3]
Lermuzeaux M(2017)New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma Melanoma Res 19 682-685
[4]
Ekpe K(2017)Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia Eur J Heart Fail 52 274-288
[5]
Ederhy S(2010)Myocarditis Prog Cardiovasc Dis 1003 187-221
[6]
Pages C(2017)Cardiac autoimmunity: myocarditis Adv Exp Med Biol 14 247-249
[7]
Lebbe C(2018)Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american Society of Clinical Oncology Clinical Practice Guideline Summary J Oncol Pract 28 1326-1333
[8]
Baldetti L(2007)A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis Eur Heart J 19 63-671
[9]
Melillo F(2017)Myocarditis: a clinical overview Curr Cardiol Rep 56 667-564
[10]
Beneduce A(2018)Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma Clin Toxicol (Phila) 26 555-1931